John P Chalmers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7148199/publications.pdf

Version: 2024-02-01

451 papers	41,678 citations	4370 86 h-index	2736 192 g-index
457 all docs	457 docs citations	457 times ranked	36819 citing authors

#	Article	IF	Citations
1	Associations of Early Systolic Blood Pressure Control and Outcome After Thrombolysis-Eligible Acute Ischemic Stroke: Results From the ENCHANTED Study. Stroke, 2022, 53, 779-787.	1.0	14
2	Early lowering of blood pressure after acute intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 6-13.	0.9	25
3	J-shape relation of blood pressure reduction and outcome in acute intracerebral hemorrhage: A pooled analysis of INTERACT2 and ATACH-II individual participant data. International Journal of Stroke, 2022, , 174749302110640.	2.9	14
4	Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial: Rationale, design and progress. International Journal of Stroke, 2022, 17, 1156-1162.	2.9	3
5	The Blood Pressure Lowering Treatment Trialistsâ€™ Collaboration. Journal of Hypertension, 2022, Publish Ahead of Print, .	0.3	4
6	Clinical outcomes by atherosclerotic cardiovascular disease risk score and blood pressure level in high risk individuals with type 2 diabetes. Journal of Human Hypertension, 2022, , .	1.0	1
7	Effects of glucose and blood pressure reduction on subclinical cardiac damage: Results from ADVANCE. International Journal of Cardiology, 2022, 358, 103-109.	0.8	2
8	Validation of the simplified modified Rankin scale for stroke trials: Experience from the ENCHANTED alteplase-dose arm. International Journal of Stroke, 2021, 16, 222-228.	2.9	9
9	Ultra-low-dose quadruple combination blood pressureâ€“lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol. American Heart Journal, 2021, 231, 56-67.	1.2	14
10	Intensive versus guidelineâ€recommended blood pressure reduction in acute lacunar stroke with intravenous thrombolysis therapy: The ENCHANTED trial. European Journal of Neurology, 2021, 28, 783-793.	1.7	8
11	Economic Evaluation of a New Polygenic Risk Score to Predict Nephropathy in Adult Patients With Type 2 Diabetes. Canadian Journal of Diabetes, 2021, 45, 129-136.	0.4	8
12	Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses. Diabetologia, 2021, 64, 275-287.	2.9	140
13	Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor. Kidney International Reports, 2021, 6, 284-295.	0.4	8
14	Novel Lipid Species for Detecting and Predicting Atrial Fibrillation in Patients With Type 2 Diabetes. Diabetes, 2021, 70, 255-261.	0.3	9
15	Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. Kidney International, 2021, 99, 926-939.	2.6	42
16	History of lower-limb complications and risk of cancer death in people with type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 3.	2.7	11
17	Associations of an Abnormal Physiological Score With Outcomes in Acute Intracerebral Hemorrhage. Stroke, 2021, 52, 722-725.	1.0	9
18	The comparative effects of intensive glucose lowering in diabetes patients aged below or above 65â€‰years: Results from the <scp>ADVANCE</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1292-1300.	2.2	7

#	Article	IF	Citations
19	Smoking influences outcome in patients who had thrombolysed ischaemic stroke: the ENCHANTED study. Stroke and Vascular Neurology, 2021, 6, e000493.	1.5	6
20	Low-Dose vs Standard-Dose Alteplase in Acute Lacunar Ischemic Stroke. Neurology, 2021, 96, e1512-e1526.	1.5	16
21	Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the <scp>ADVANCE</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1420-1425.	2.2	3
22	The Impact of Frailty on the Effectiveness and Safety of Intensive Glucose Control and Blood Pressureâ€"Lowering Therapy for People With Type 2 Diabetes: Results From the ADVANCE Trial. Diabetes Care, 2021, 44, 1622-1629.	4.3	29
23	Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet, The, 2021, 397, 1625-1636.	6.3	414
24	Sex differences in risk factors for cognitive decline and dementia, including death as a competing risk, in individuals with diabetes: Results from the <scp>ADVANCE</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1775-1785.	2.2	12
25	Thrombolysis outcomes according to arterial characteristics of acute ischemic stroke by alteplase dose and blood pressure target. International Journal of Stroke, 2021, , 174749302110254.	2.9	0
26	Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis. PLoS Medicine, 2021, 18, e1003599.	3.9	16
27	Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control. Diabetologia, 2021, 64, 2012-2025.	2.9	24
28	PROGRESS in Blood Pressure Control for the Prevention of Secondary Stroke. Cerebrovascular Diseases, 2021, 50, 1-5.	0.8	0
29	Regional Differences in Early BP Management After Acute Ischemic Stroke in the ENCHANTED International Randomized Controlled Trials. Frontiers in Neurology, 2021, 12, 687862.	1.1	1
30	Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet, The, 2021, 398, 1053-1064.	6.3	133
31	Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet, The, 2021, 398, 1043-1052.	6.3	74
32	Disparities between Asian and Non-Asian Thrombolyzed Acute Ischemic Stroke Patients in the Enhanced Control of Hypertension and Thrombolysis Stroke Trial. Cerebrovascular Diseases, 2021, 50, 560-566.	0.8	5
33	Comparative effects of intensive-blood pressure versus standard-blood pressure-lowering treatment in patients with severe ischemic stroke in the ENCHANTED trial. Journal of Hypertension, 2021, 39, 280-285.	0.3	13
34	Impact of Model Choice When Studying the Relationship Between Blood Pressure Variability and Risk of Stroke Recurrence. Hypertension, 2021, 78, 1520-1526.	1.3	4
35	Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet, The, 2021, 398, 1803-1810.	6.3	64
36	Sex differences in predictors for cognitive decline and dementia in people with stroke or transient ischemic attack in the PROGRESS trial. International Journal of Stroke, 2021, , 174749302110592.	2.9	2

#	Article	IF	Citations
37	Glycemic excursions and subclinical cardiac damage in adults with type 2 diabetes: Results from the ADVANCE Trial. Diabetes Research and Clinical Practice, 2021, 182, 109148.	1.1	0
38	Is Blood Pressure Lowering in the Very Elderly With Previous Stroke Associated With a Higher Risk of Adverse Events?. Journal of the American Heart Association, 2021, 10, e022240.	1.6	4
39	Who will benefit more from low-dose alteplase in acute ischemic stroke?. International Journal of Stroke, 2020, 15, 39-45.	2.9	9
40	The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 152-162.	1.8	17
41	Intensive glucoseâ€lowering and the risk of vascular events and premature death in patients with decreased kidney function: The ADVANCE trial. Diabetes, Obesity and Metabolism, 2020, 22, 452-457.	2.2	7
42	Lancet Commission on Hypertension group position statement on the global improvement of accuracy standards for devices that measure blood pressure. Journal of Hypertension, 2020, 38, 21-29.	0.3	93
43	Comparison of ABC Methods with Computerized Estimates of Intracerebral Hemorrhage Volume: The INTERACT2 Study. Cerebrovascular Diseases Extra, 2020, 9, 148-154.	0.5	12
44	Observational analyses from ADVANCE and ADVANCEâ€ON. Diabetes, Obesity and Metabolism, 2020, 22, 19-32.	2.2	1
45	Ethnicity and Other Determinants of Quality of Functional Outcome in Acute Ischemic Stroke. Stroke, 2020, 51, 588-593.	1.0	4
46	Association of anthropometry and weight change with risk of dementia and its major subtypes: A metaâ€analysis consisting 2.8 million adults with 57 294 cases of dementia. Obesity Reviews, 2020, 21, e12989.	3.1	62
47	Sex differences in treatment, radiological features and outcome after intracerebral haemorrhage: Pooled analysis of Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage trials 1 and 2. European Stroke Journal, 2020, 5, 345-350.	2.7	13
48	Brain Imaging Signs and Health-Related Quality of Life after Acute Ischemic Stroke: Analysis of ENCHANTED Alteplase Dose Arm. Cerebrovascular Diseases, 2020, 49, 427-436.	0.8	2
49	Future Directions for Dementia Risk Reduction and Prevention Research: An International Research Network on Dementia Prevention Consensus. Journal of Alzheimer's Disease, 2020, 78, 3-12.	1.2	22
50	Plasma fatty acids and the risk of vascular disease and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study. Diabetologia, 2020, 63, 1637-1647.	2.9	16
51	Sexâ€specific associations between cardiovascular risk factors and myocardial infarction in patients with type 2 diabetes: The <scp>ADVANCEâ€ON</scp> study. Diabetes, Obesity and Metabolism, 2020, 22, 1818-1826.	2.2	9
52	Thrombolysis Outcomes in Acute Ischemic Stroke by Fluid-Attenuated Inversion Recovery Hyperintense Arteries. Stroke, 2020, 51, 2240-2243.	1.0	7
53	Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A1c in the ADVANCE Trial. Diabetes Care, 2020, 43, 1293-1299.	4.3	15
54	Alternative kidney filtration markers and the risk of major macrovascular and microvascular events, and <scp>allâ€cause</scp> mortality in individuals with type 2 diabetes in the <scp>ADVANCE</scp> trial. Journal of Diabetes, 2020, 12, 929-941.	0.8	5

#	Article	IF	Citations
55	Utility-Weighted Modified Rankin Scale Scores for the Assessment of Stroke Outcome. Stroke, 2020, 51, 2411-2417.	1.0	14
56	Investigation of antihypertensive class, dementia, and cognitive decline. Neurology, 2020, 94, e267-e281.	1.5	78
57	Medication reminder applications to improve adherence in coronary heart disease: a randomised clinical trial. Heart, 2019, 105, 323-329.	1.2	68
58	Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a preplanned pooled analysis of individual participant data. Lancet Neurology, The, 2019, 18, 857-864.	4.9	133
59	The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study. Diabetologia, 2019, 62, 1988-1997.	2.9	44
60	Outcome Assessment by Central Adjudicators Versus Site Investigators in Stroke Trials. Stroke, 2019, 50, 2187-2196.	1.0	13
61	Sex differences in treatment and outcome after stroke. Neurology, 2019, 93, e2170-e2180.	1.5	90
62	Changes in plasma lipids predict pravastatin efficacy in secondary prevention. JCI Insight, 2019, 4, .	2.3	13
63	Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialistsâ€™ Collaboration (BPLTTC). BMJ Open, 2019, 9, e028698.	0.8	26
64	Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 862-872.	2.2	29
65	Determinants of Early Versus Delayed Neurological Deterioration in Intracerebral Hemorrhage. Stroke, 2019, 50, 1409-1414.	1.0	47
66	Effects of Blood Pressure Lowering on Clinical Outcomes According to Baseline Blood Pressure and Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus. Hypertension, 2019, 73, 1291-1299.	1.3	26
67	Response of 1,5â€anhydroglucitol level to intensive glucoseâ€and bloodâ€pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial. Diabetes, Obesity and Metabolism, 2019, 21, 2017-2023.	2.2	9
68	Blood pressure variability and outcome in acute ischemic and hemorrhagic stroke: a post hoc analysis of the HeadPoST study. Journal of Human Hypertension, 2019, 33, 411-418.	1.0	19
69	Infratentorial Intracerebral Hemorrhage. Stroke, 2019, 50, 1257-1259.	1.0	19
70	C-peptide predicts all-cause and cardiovascular death in a cohort of individuals with newly diagnosed type 2 diabetes. The Skaraborg diabetes register. Diabetes Research and Clinical Practice, 2019, 150, 174-183.	1.1	14
71	The National Institute for Health Research Hyperacute Stroke Research Centres and the ENCHANTED trial: the impact of enhanced research infrastructure on trial metrics and patient outcomes. Health Research Policy and Systems, 2019, 17, 19.	1.1	1
72	Applicability of ENCHANTED trial results to current acute ischemic stroke patients eligible for intravenous thrombolysis in England and Wales: Comparison with the Sentinel Stroke National Audit Programme registry. International Journal of Stroke, 2019, 14, 678-685.	2.9	1

#	Article	IF	Citations
73	New Blood Pressure Guidelines Pose Difficult Choices for Australian Physicians. Circulation Research, 2019, 124, 975-977.	2.0	13
74	Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. Lancet, The, 2019, 393, 877-888.	6.3	178
75	Determinants of the high admission blood pressure in mild-to-moderate acute intracerebral hemorrhage. Journal of Hypertension, 2019, 37, 1463-1466.	0.3	6
76	EPHA4 regulates vascular smooth muscle cell contractility and is a sex-specific hypertension risk gene in individuals with type 2 diabetes. Journal of Hypertension, 2019, 37, 775-789.	0.3	10
77	Interaction of Blood Pressure Lowering and Alteplase Dose in Acute Ischemic Stroke: Results of the Enhanced Control of Hypertension and Thrombolysis Stroke Study. Cerebrovascular Diseases, 2019, 48, 207-216.	0.8	3
78	Effects of blood pressure lowering on cardiovascular events, in the context of regression to the mean. Journal of Hypertension, 2019, 37, 16-23.	0.3	37
79	Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus. Hypertension, 2019, 73, 84-91.	1.3	40
80	Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500Â000 patients with Type 2 diabetes mellitus. European Heart Journal, 2019, 40, 2899-2906.	1.0	59
81	Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes and Endocrinology,the, 2019, 7, 115-127.	5.5	199
82	Statistical analysis plan for evaluating different intensities of blood pressure control in the ENhanced Control of Hypertension And Thrombolysis strokE stuDy. International Journal of Stroke, 2019, 14, 555-558.	2.9	10
83	Use of the waistâ€toâ€height ratio to predict cardiovascular risk in patients with diabetes: <scp>R</scp>esults from the <scp>ADVANCEâ€ON</scp> study. Diabetes, Obesity and Metabolism, 2018, 20, 1903-1910.	2.2	29
84	Salt intake and dietary sources of salt on weekdays and weekend days in Australian adults. Public Health Nutrition, 2018, 21, 2174-2182.	1.1	4
85	Associations between body mass index and the risk of renal events in patients with type 2 diabetes. Nutrition and Diabetes, 2018, 8, 7.	1.5	32
86	Comparative effects of low-dose versus standard-dose alteplase in ischemic patients with prior stroke and/or diabetes mellitus: The ENCHANTED trial. Journal of the Neurological Sciences, 2018, 387, 1-5.	0.3	9
87	Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia, 2018, 61, 780-789.	2.9	42
88	Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial. Diabetologia, 2018, 61, 1581-1591.	2.9	76
89	Lipid-Lowering Pretreatment and Outcome Following Intravenous Thrombolysis for Acute Ischaemic Stroke: A Post Hoc Analysis of the Enhanced Control of Hypertension and Thrombolysis Stroke Study Trial. Cerebrovascular Diseases, 2018, 45, 213-220.	0.8	4
90	Current status of intravenous tissue plasminogen activator dosage for acute ischaemic stroke: an updated systematic review. Stroke and Vascular Neurology, 2018, 3, 28-33.	1.5	13

#	Article	IF	Citations
91	Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON. Diabetes Care, 2018, 41, 163-170.	4.3	46
92	NIHSS cut point for predicting outcome in supra- vs infratentorial acute ischemic stroke. Neurology, 2018, 91, e1695-e1701.	1.5	13
93	Large-scale plasma lipidomic profiling identifies lipids that predict cardiovascular events in secondary prevention. JCI Insight, 2018, 3, .	2.3	100
94	Response to Comment on Ohkuma et al. Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial. Diabetes Care 2017;40:1203â€“1209. Diabetes Care, 2018, 41, e39-e39.	4.3	0
95	Clinical Utility of Electronic Alberta Stroke Program Early Computed Tomography Score Software in the ENCHANTED Trial Database. Stroke, 2018, 49, 1407-1411.	1.0	31
96	Relationship Between Plasma 8â€OHâ€Deoxyguanosine and Cardiovascular Disease and Survival in Type 2 Diabetes Mellitus: Results From the ADVANCE Trial. Journal of the American Heart Association, 2018, 7, .	1.6	26
97	Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data. PLoS Medicine, 2018, 15, e1002538.	3.9	67
98	Low- versus Standard-Dose Intravenous Alteplase in the Context of Bridging Therapy for Acute Ischemic Stroke: A Korean ENCHANTED Study. Journal of Stroke, 2018, 20, 131-139.	1.4	12
99	Prognostic significance of delayed intraventricular haemorrhage in the INTERACT studies. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 19-24.	0.9	21
100	Risk factors and consequences of decreased kidney function in nursing home residents: A longitudinal study. Geriatrics and Gerontology International, 2017, 17, 791-797.	0.7	8
101	Intracerebral hemorrhage location and outcome among INTERACT2 participants. Neurology, 2017, 88, 1408-1414.	1.5	101
102	Associations with health-related quality of life after intracerebral haemorrhage: pooled analysis of INTERACT studies. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 70-75.	0.9	21
103	Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. Lancet, The, 2017, 389, 1035-1042.	6.3	102
104	Side effects and tolerability of combination blood pressure lowering according to blood pressure levels. Journal of Hypertension, 2017, 35, 1318-1325.	0.3	4
105	Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy. Stroke, 2017, 48, 1877-1883.	1.0	42
106	Dietary salt intake in the Australian population. Public Health Nutrition, 2017, 20, 1887-1894.	1.1	22
107	Practice Patterns for Neurosurgical Utilization and Outcome in Acute Intracerebral Hemorrhage: Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trials 1 and 2 Studies. Neurosurgery, 2017, 81, 980-985.	0.6	9
108	Cumulative in-trial and post-trial effects of blood pressure and lipid lowering. Journal of Hypertension, 2017, 35, 905-913.	0.3	14

#	Article	IF	Citations
109	Using administrative data to look at changes in the level and distribution of out-of-pocket medical expenditure: An example using Medicare data from Australia. Health Policy, 2017, 121, 426-433.	1.4	16
110	Evidence from single nucleotide polymorphism analyses of ADVANCE study demonstrates EFNB3 as a hypertension risk gene. Scientific Reports, 2017, 7, 44114.	1.6	10
111	Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes and Endocrinology,the, 2017, 5, 431-437.	5.5	379
112	Early Cognitive Impairment after Intracerebral Hemorrhage in the INTERACT1 Study. Cerebrovascular Diseases, 2017, 44, 320-324.	0.8	19
113	Low-Dose vs Standard-Dose Alteplase for Patients With Acute Ischemic Stroke. JAMA Neurology, 2017, 74, 1328.	4.5	33
114	Characteristics, management and response to alteplase in China versus non-China participants of the ENCHANTED trial. Stroke and Vascular Neurology, 2017, 2, 53-58.	1.5	5
115	Australian general practitioners initiate statin therapy primarily on the basis of lipid levels; New Zealand general practitioners use absolute risk. Health Policy, 2017, 121, 1233-1239.	1.4	4
116	MEDication reminder APPs to improve medication adherence in Coronary Heart Disease (MedApp-CHD) Study: a randomised controlled trial protocol. BMJ Open, 2017, 7, e017540.	0.8	49
117	Microvascular outcomes in type 2 diabetes â€“ Authors' reply. Lancet Diabetes and Endocrinology,the, 2017, 5, 580.	5.5	0
118	Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data. Lancet Diabetes and Endocrinology,the, 2017, 5, 718-728.	5.5	110
119	Frequency, determinants, and effects of early seizures after thrombolysis for acute ischemic stroke. Neurology: Clinical Practice, 2017, 7, 324-332.	0.8	19
120	Positive impact of the participation in the ENCHANTED trial in reducing Door-to-Needle Time. Scientific Reports, 2017, 7, 14168.	1.6	1
121	Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial. Diabetes Care, 2017, 40, 1203-1209.	4.3	38
122	Guidelines Under Fire Again!. Hypertension, 2017, 70, 238-239.	1.3	1
123	PROX1 gene CC genotype as a major determinant of early onset of type 2 diabetes in slavic study participants from Action in Diabetes and Vascular Disease. Journal of Hypertension, 2017, 35, S24-S32.	0.3	28
124	Guidelines under fire again!*. Journal of Hypertension, 2017, 35, 1567-1568.	0.3	2
125	Prognostic Value of Variability in Systolic Blood Pressure Related to Vascular Events and Premature Death in Type 2 Diabetes Mellitus. Hypertension, 2017, 70, 461-468.	1.3	61
126	Withdrawal of active treatment after intracerebral haemorrhage in the INTERACT2 study. Age and Ageing, 2017, 46, 329-332.	0.7	5

#	Article	IF	Citations
127	Early Blood Pressure Lowering Does Not Reduce Growth of Intraventricular Hemorrhage following Acute Intracerebral Hemorrhage: Results of the INTERACT Studies. Cerebrovascular Diseases Extra, 2017, 6, 71-75.	0.5	11
128	Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes. Cardiovascular Diabetology, 2017, 16, 95.	2.7	71
129	Efficacy and Safety of Quarter-Dose Blood Pressureâ€“Lowering Agents. Hypertension, 2017, 70, 85-93.	1.3	48
130	Influence of Renal Impairment on Outcome for Thrombolysis-Treated Acute Ischemic Stroke. Stroke, 2017, 48, 2605-2609.	1.0	34
131	Examination of an eHealth literacy scale and a health literacy scale in a population with moderate to high cardiovascular risk: Rasch analyses. PLoS ONE, 2017, 12, e0175372.	1.1	74
132	eHealth Literacy: Predictors in a Population With Moderate-to-High Cardiovascular Risk. JMIR Human Factors, 2017, 4, e4.	1.0	121
133	Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studies. BMC Cancer, 2016, 16, 488.	1.1	78
134	Low Ambient Temperature and Intracerebral Hemorrhage: The INTERACT2 Study. PLoS ONE, 2016, 11, e0149040.	1.1	15
135	Risks associated with permanent discontinuation of blood pressure-lowering medications in patients with type 2 diabetes. Journal of Hypertension, 2016, 34, 781-787.	0.3	34
136	Early blood pressure lowering in patients with intracerebral haemorrhage and prior use of antithrombotic agents: pooled analysis of the INTERACT studies. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1330-1335.	0.9	14
137	Interventions to improve medication adherence in coronary disease patients: A systematic review and meta-analysis of randomised controlled trials. European Journal of Preventive Cardiology, 2016, 23, 1065-1076.	0.8	43
138	Admission Heart Rate Predicts Poor Outcomes in Acute Intracerebral Hemorrhage. Stroke, 2016, 47, 1479-1485.	1.0	26
139	Significance of Hematoma Shape and Density in Intracerebral Hemorrhage. Stroke, 2016, 47, 1227-1232.	1.0	48
140	Prophylactic heparin in acute intracerebral hemorrhage: a propensity score-matched analysis of the INTERACT2 study. International Journal of Stroke, 2016, 11, 549-556.	2.9	12
141	Degree and Timing of Intensive Blood Pressure Lowering on Hematoma Growth in Intracerebral Hemorrhage. Stroke, 2016, 47, 1651-1653.	1.0	46
142	Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke. New England Journal of Medicine, 2016, 374, 2313-2323.	13.9	352
143	Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. Diabetologia, 2016, 59, 2603-2612.	2.9	8
144	Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study. Cardiovascular Diabetology, 2016, 15, 129.	2.7	73

#	Article	IF	Citations
145	Absence of Peripheral Pulses and Risk of Major Vascular Outcomes in Patients With Type 2 Diabetes. Diabetes Care, 2016, 39, 2270-2277.	4.3	26
146	Circadian variation in clinical features and outcome of intracerebral hemorrhage: The INTERACT studies. Chronobiology International, 2016, 33, 1182-1187.	0.9	6
147	Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes. Diabetes Care, 2016, 39, 1796-1803.	4.3	79
148	Reduced blood pressure after smooth muscle EFNB2 deletion and the potential association of EFNB2 mutation with human hypertension risk. European Journal of Human Genetics, 2016, 24, 1817-1825.	1.4	16
149	Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus. Circulation, 2016, 134, 1637-1650.	1.6	205
150	Strategies to meet the need for long-term data. Journal of Hypertension, 2016, 34, 1473-1479.	0.3	6
151	Prognostic Significance of Hyponatremia in Acute Intracerebral Hemorrhage: Pooled Analysis of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial Studies*. Critical Care Medicine, 2016, 44, 1388-1394.	0.4	37
152	Effects of a community-based salt reduction program in a regional Australian population. BMC Public Health, 2016, 16, 388.	1.2	31
153	Changes in Quality of Life Associated with Complications of Diabetes: Results from the ADVANCE Study. Value in Health, 2016, 19, 36-41.	0.1	83
154	White blood cell count and clinical outcomes after intracerebral hemorrhage: The INTERACT2 trial. Journal of the Neurological Sciences, 2016, 361, 112-116.	0.3	43
155	Genome-wide Association Studies Identify Genetic Loci Associated With Albuminuria in Diabetes. Diabetes, 2016, 65, 803-817.	0.3	131
156	Management of the hypertensive patient with elevated heart rate. Journal of Hypertension, 2016, 34, 813-821.	0.3	116
157	Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. Diabetes Care, 2016, 39, 694-700.	4.3	184
158	Significance of Cerebral Small-Vessel Disease in Acute Intracerebral Hemorrhage. Stroke, 2016, 47, 701-707.	1.0	59
159	Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. Nature Communications, 2016, 7, 10023.	5.8	412
160	Prognostic Significance of Hyperglycemia in Acute Intracerebral Hemorrhage. Stroke, 2016, 47, 682-688.	1.0	103
161	Estimated GFR and the Effect of Intensive Blood Pressure Lowering After Acute Intracerebral Hemorrhage. American Journal of Kidney Diseases, 2016, 68, 94-102.	2.1	31
162	The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax) Tj ETQq0 0 0 rgBT /Overlock 10	0.8	40

#	Article	IF	Citations
163	Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet, The, 2016, 387, 957-967.	6.3	2,464
164	Using Classification and Regression Trees (CART) to Identify Prescribing Thresholds for Cardiovascular Disease. Pharmacoeconomics, 2016, 34, 195-205.	1.7	21
165	Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet, The, 2016, 387, 435-443.	6.3	792
166	Mobile Phone Apps to Improve Medication Adherence: A Systematic Stepwise Process to Identify High-Quality Apps. JMIR MHealth and UHealth, 2016, 4, e132.	1.8	217
167	Hypertension Guidelines: Timely New Initiatives from East Asia. Pulse, 2015, 3, 1-3.	0.9	3
168	Measuring the Progressivity of the Pharmaceutical Benefits Scheme. Australian Economic Review, 2015, 48, 122-132.	0.4	6
169	Blood pressure control after a stroke. Journal of Hypertension, 2015, 33, 2022-2024.	0.3	1
170	Poor Utility of Grading Scales in Acute Intracerebral Hemorrhage: Results from the Interact2 Trial. International Journal of Stroke, 2015, 10, 1101-1107.	2.9	25
171	Dietary Salt Intake and Discretionary Salt Use in Two General Population Samples in Australia: 2011 and 2014. Nutrients, 2015, 7, 10501-10512.	1.7	35
172	Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes and Endocrinology,the, 2015, 3, 514-525.	5.5	604
173	Prognostic Significance of Perihematomal Edema in Acute Intracerebral Hemorrhage. Stroke, 2015, 46, 1009-1013.	1.0	132
174	Significance of Intraventricular Hemorrhage in Acute Intracerebral Hemorrhage. Stroke, 2015, 46, 653-658.	1.0	40
175	Statistical Analysis Plan for Evaluating Low- vs. Standard-Dose Alteplase in the Enhanced Control of Hypertension and Thrombolysis Stroke Study (Enchanted). International Journal of Stroke, 2015, 10, 1313-1315.	2.9	28
176	Can blood pressure-lowering therapy reduce the risk of cognitive decline in the elderly?. Journal of Hypertension, 2015, 33, 2029-2031.	0.3	2
177	The effects of reduced copayments on discontinuation and adherence failure to statin medication in Australia. Health Policy, 2015, 119, 620-627.	1.4	20
178	Endothelial Gata5 transcription factor regulates blood pressure. Nature Communications, 2015, 6, 8835.	5.8	35
179	Optimal achieved blood pressure in acute intracerebral hemorrhage. Neurology, 2015, 84, 464-471.	1.5	101
180	The development and feasibility of a composite score of echocardiographic indices that may stratify outcome in patients with diabetes mellitus. International Journal of Cardiology, 2015, 182, 244-249.	0.8	0

#	Article	IF	Citations
181	Higher mortality in patients with right hemispheric intracerebral haemorrhage: INTERACT1 and 2. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1319-1323.	0.9	12
182	Older age is a strong predictor for poor outcome in intracerebral haemorrhage: the INTERACT2 study. Age and Ageing, 2015, 44, 422-427.	0.7	55
183	Magnitude of Blood Pressure Reduction and Clinical Outcomes in Acute Intracerebral Hemorrhage. Hypertension, 2015, 65, 1026-1032.	1.3	44
184	Effects of Blood Pressure Reduction in Mild Hypertension. Annals of Internal Medicine, 2015, 162, 184-191.	2.0	219
185	Rationale, Design, and Progress of the ENhanced Control of Hypertension ANd Thrombolysis Stroke Study (ENCHANTED) Trial: An International Multicenter 2 Ã— 2 Quasi-Factorial Randomized Controlled Trial of Low- vs. Standard-Dose rt-PA and Early Intensive vs. Guideline-Recommended Blood Pressure Lowering in Patients with Acute Ischaemic Stroke Eligible for Thrombolysis Treatment. International Journal of Stroke, 2015, 10, 778-788.	2.9	82
186	Yogaâ€™s effect on inflammatory biomarkers and metabolic risk factors in a high risk population â€“ a controlled trial in primary care. BMC Cardiovascular Disorders, 2015, 15, 91.	0.7	18
187	Relationship Between Levels of Advanced Glycation End Products and Their Soluble Receptor and Adverse Outcomes in Adults With Type 2 Diabetes. Diabetes Care, 2015, 38, 1891-1897.	4.3	62
188	Mannitol and Outcome in Intracerebral Hemorrhage. Stroke, 2015, 46, 2762-2767.	1.0	51
189	Ambient Temperature and Volume of Perihematomal Edema in Acute Intracerebral Haemorrhage: The INTERACT1 Study. International Journal of Stroke, 2015, 10, 25-27.	2.9	13
190	Predicting the Effects of Blood Pressureâ€“Lowering Treatment on Major Cardiovascular Events for Individual Patients With Type 2 Diabetes Mellitus. Hypertension, 2015, 65, 115-121.	1.3	24
191	The speed of ultraearly hematoma growth in acute intracerebral hemorrhage. Neurology, 2014, 83, 2232-2238.	1.5	28
192	Response to Comment on Hillis et al. The Relative and Combined Ability of High-Sensitivity Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Cardiovascular Events and Death in Patients With Type 2 Diabetes. Diabetes Care 2014;37:295â€“303. Diabetes Care, 2014, 37, e154-e154.	4.3	1
193	Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia, 2014, 57, 2465-2474.	2.9	346
194	Subarachnoid Extension of Intracerebral Hemorrhage and 90-Day Outcomes in INTERACT2. Stroke, 2014, 45, 258-260.	1.0	21
195	Clinical Practice Guidelines for the Management of Hypertension in the Community. Journal of Clinical Hypertension, 2014, 16, 14-26.	1.0	768
196	Are the effects of telmisartan more marked in hypertensive patients?. Journal of Hypertension, 2014, 32, 1201-1202.	0.3	1
197	How far to lower blood pressure in the long term, after a stroke?. Journal of Hypertension, 2014, 32, 746-748.	0.3	1
198	Clinical Practice Guidelines for the Management of Hypertension in the Community. Journal of Hypertension, 2014, 32, 3-15.	0.3	498

#	Article	IF	Citations
199	Ambient Temperature and Severity of Intracerebral Haemorrhage: The INTERACT1 Study. Neuroepidemiology, 2014, 42, 169-173.	1.1	5
200	Revisiting lifestyle risk index assessment in a large Australian sample: Should sedentary behavior and sleep be included as additional risk factors?. Preventive Medicine, 2014, 60, 102-106.	1.6	43
201	Blood pressure variability and outcome after acute intracerebral haemorrhage: a post-hoc analysis of INTERACT2, a randomised controlled trial. Lancet Neurology, The, 2014, 13, 364-373.	4.9	193
202	Blood pressure and cerebral ischemia. Neurology, 2014, 82, 1018-1019.	1.5	0
203	Circulating Inflammatory Markers and the Risk of Vascular Complications and Mortality in People With Type 2 Diabetes and Cardiovascular Disease or Risk Factors: The ADVANCE Study. Diabetes, 2014, 63, 1115-1123.	0.3	118
204	Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial. Diabetes Care, 2014, 37, 2359-2365.	4.3	284
205	Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. New England Journal of Medicine, 2014, 371, 1392-1406.	13.9	520
206	Effects of Combination of Perindopril, Indapamide, and Calcium Channel Blockers in Patients With Type 2 Diabetes Mellitus. Hypertension, 2014, 63, 259-264.	1.3	55
207	The Relative and Combined Ability of High-Sensitivity Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Cardiovascular Events and Death in Patients With Type 2 Diabetes. Diabetes Care, 2014, 37, 295-303.	4.3	65
208	Protocol for the implementation and evaluation of a community-based intervention seeking to reduce dietary salt intake in Lithgow, Australia. BMC Public Health, 2014, 14, 357.	1.2	10
209	The association of knowledge, attitudes and behaviours related to salt with 24-hour urinary sodium excretion. International Journal of Behavioral Nutrition and Physical Activity, 2014, 11, 47.	2.0	60
210	Do Cardiac Biomarkers NT-proBNP and hsTnT Predict Microvascular Events in Patients With Type 2 Diabetes? Results From the ADVANCE Trial. Diabetes Care, 2014, 37, 2202-2210.	4.3	32
211	The Relationship Between Alcohol Consumption and Vascular Complications and Mortality in Individuals With Type 2 Diabetes. Diabetes Care, 2014, 37, 1353-1359.	4.3	79
212	Degree of blood pressure reduction and recurrent stroke: the PROGRESS trial. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1284-1285.	0.9	18
213	Acute post-stroke blood pressure relative to premorbid levels in intracerebral haemorrhage versus major ischaemic stroke: a population-based study. Lancet Neurology, The, 2014, 13, 374-384.	4.9	103
214	Salt intake assessed by 24â€...h urinary sodium excretion in a random and opportunistic sample in Australia. BMJ Open, 2014, 4, e003720.	0.8	73
215	Rapid Blood-Pressure Lowering in Patients With Acute Intracerebral Hemorrhage. Survey of Anesthesiology, 2014, 58, 24-26.	0.1	9
216	Rapid Blood-Pressure Lowering in Patients with Acute Intracerebral Hemorrhage. New England Journal of Medicine, 2013, 368, 2355-2365.	13.9	1,269

#	Article	IF	Citations
217	Current issues with dual inhibition of the reninâ€“angiotensin system. Journal of Hypertension, 2013, 31, 261-262.	0.3	0
218	Baseline Cognitive Function, Recurrent Stroke, and Risk of Dementia in Patients With Stroke. Stroke, 2013, 44, 1790-1795.	1.0	62
219	Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International, 2013, 83, 517-523.	2.6	256
220	Erectile Dysfunction Severity as a Risk Marker for Cardiovascular Disease Hospitalisation and All-Cause Mortality: A Prospective Cohort Study. PLoS Medicine, 2013, 10, e1001372.	3.9	112
221	Effects of Visit-to-Visit Variability in Systolic Blood Pressure on Macrovascular and Microvascular Complications in Patients With Type 2 Diabetes Mellitus. Circulation, 2013, 128, 1325-1334.	1.6	189
222	Circulating bone morphogenetic protein-7 and transforming growth factor-Î²1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney International, 2013, 83, 278-284.	2.6	47
223	The Association of High-Density Lipoprotein Cholesterol with Cancer Incidence in Type II Diabetes: A Case of Reverse Causality?. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1628-1633.	1.1	5
224	Statistical Analysis Plan for the Second Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2). International Journal of Stroke, 2013, 8, 327-328.	2.9	8
225	Blood-Pressure Lowering in Acute Intracerebral Hemorrhage. New England Journal of Medicine, 2013, 369, 1273-1275.	13.9	17
226	The Authors Reply. Kidney International, 2013, 84, 622.	2.6	34
227	Global survey of current practice in management of hypertension as reported by societies affiliated with the international society of hypertension. Journal of Hypertension, 2013, 31, 1043-1048.	0.3	38
228	Effects of the Endpoint Adjudication Process on the Results of a Randomised Controlled Trial: The ADVANCE Trial. PLoS ONE, 2013, 8, e55807.	1.1	34
229	The Post Hoc Use of Randomised Controlled Trials to Explore Drug Associated Cancer Outcomes: Methodological Challenges. Current Drug Safety, 2013, 8, 371-378.	0.3	3
230	Cerebrovascular Disease in Hypertension. , 2013, , 303-312.		0
231	Effects of Intensive Blood Pressure Lowering on Cardiovascular and Renal Outcomes: A Systematic Review and Meta-Analysis. PLoS Medicine, 2012, 9, e1001293.	3.9	389
232	Low HDL Cholesterol and the Risk of Diabetic Nephropathy and Retinopathy. Diabetes Care, 2012, 35, 2201-2206.	4.3	98
233	Earlier Blood Pressure-Lowering and Greater Attenuation of Hematoma Growth in Acute Intracerebral Hemorrhage. Stroke, 2012, 43, 2236-2238.	1.0	42
234	Genomewide Association Study Using a High-Density Single Nucleotide Polymorphism Array and Case-Control Design Identifies a Novel Essential Hypertension Susceptibility Locus in the Promoter Region of Endothelial NO Synthase. Hypertension, 2012, 59, 248-255.	1.3	144

#	Article	IF	Citations
235	Cognitive Function and Dementia in Hypertension: Epidemiologic and Therapeutic Aspects. , 2012, , 399-412.		0
236	Making Good Use of Diastolic and Systolic Blood Pressures in the Management of Hypertension. Hypertension, 2012, 60, 1110-1111.	1.3	0
237	Resting Heart Rate and the Risk of Microvascular Complications in Patients With Type 2 Diabetes Mellitus. Journal of the American Heart Association, 2012, 1, e002832.	1.6	59
238	Cardiovascular risk management in chronic kidney disease in general practice (the AusHEART study). Nephrology Dialysis Transplantation, 2012, 27, 1396-1402.	0.4	42
239	The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation, 2012, 27, 3337-3344.	0.4	31
240	Effects of Blood Pressure Lowering on Intracranial and Extracranial Bleeding in Patients on Antithrombotic Therapy. Stroke, 2012, 43, 1675-1677.	1.0	49
241	Cost-effective reduction in stroke. Journal of Hypertension, 2012, 30, 1706-1707.	0.3	5
242	Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet, The, 2012, 380, 1662-1673.	6.3	984
243	Prediction of Kidney-Related Outcomes in Patients With Type 2 Diabetes. American Journal of Kidney Diseases, 2012, 60, 770-778.	2.1	110
244	Hematoma growth and outcomes in intracerebral hemorrhage. Neurology, 2012, 79, 314-319.	1.5	199
245	Multiple risk factor interventions and inflammatory biomarkers in high risk individuals with type 2 diabetes. Diabetes Research and Clinical Practice, 2012, 95, 386-388.	1.1	2
246	Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes. Diabetes Research and Clinical Practice, 2012, 98, 83-90.	1.1	18
247	Glycemic control and outcomes in people with diabetes and CKD. Nature Reviews Nephrology, 2012, 8, 133-134.	4.1	4
248	How fair is Medicare? The incomeâ€related distribution of Medicare benefits with special focus on chronic care items. Medical Journal of Australia, 2012, 197, 625-630.	0.8	8
249	Disparities between Prescribing of Secondary Prevention Therapies for Stroke and Coronary Artery Disease in General Practice. International Journal of Stroke, 2012, 7, 649-654.	2.9	20
250	Comparison of waist-to-hip ratio and other obesity indices as predictors of cardiovascular disease risk in people with type-2 diabetes: a prospective cohort study from ADVANCE. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 312-319.	3.1	108
251	Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney International, 2011, 79, 1341-1352.	2.6	759
252	Mortality patterns in hypertension. Journal of Hypertension, 2011, 29, S3-S7.	0.3	127

#	Article	IF	Citations
253	The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. Journal of Hypertension, 2011, 29, 4-16.	0.3	189
254	Comparability of Patient-reported Health Status. Medical Care, 2011, 49, 962-970.	1.1	14
255	A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. Journal of Hypertension, 2011, 29, 509-519.	0.3	47
256	PROGRESS: Prevention of Recurrent Stroke. Journal of Clinical Hypertension, 2011, 13, 693-702.	1.0	41
257	Statins and Intracerebral Hemorrhage. Circulation, 2011, 124, 2233-2242.	1.6	164
258	Gender disparities in the assessment and management of cardiovascular risk in primary care: the AusHEART study. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 498-503.	3.1	22
259	Blood pressure lowering in acute strokeâ€"scant joy from SCAST. Nature Reviews Cardiology, 2011, 8, 366-368.	6.1	1
260	Effects of Blood Pressure Lowering on Major Vascular Events Among Patients With Isolated Diastolic Hypertension. Stroke, 2011, 42, 2339-2341.	1.0	37
261	Is a Blood Pressure Target of <130/80 mm Hg Still Appropriate for High-Risk Patients?. Circulation, 2011, 124, 1700-1702.	1.6	16
262	Does Glycemic Control Offer Similar Benefits Among Patients With Diabetes in Different Regions of the World?. Diabetes Care, 2011, 34, 2491-2495.	4.3	32
263	Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 393-398.	3.1	127
264	Issues in the development of new combinations of blood pressure lowering drugs. Journal of Hypertension, 2010, 28, 2494-2496.	0.3	2
265	Importance of Blood Pressure Lowering in Type 2 Diabetes: Focus on ADVANCE. Journal of Cardiovascular Pharmacology, 2010, 55, 340-347.	0.8	23
266	Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension, 2010, 28, 395-400.	0.3	32
267	Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension, 2010, 28, 1141-1149.	0.3	50
268	Definition of ambulatory blood pressure targets for diagnosis and treatment of hypertension in relation to clinic blood pressure: prospective cohort study. BMJ: British Medical Journal, 2010, 340, c1104-c1104.	2.4	136
269	Cardiovascular risk perception and evidenceâ€"practice gaps in Australian general practice (the) Tj ETQq1 1 0.784314 rgBT /Overlock	0.8	118
270	Costâ€effectiveness of lowering blood pressure with a fixed combination of perindopril and indapamide in type 2 diabetes mellitus: an ADVANCE trialâ€based analysis. Medical Journal of Australia, 2010, 193, 320-324.	0.8	12

#	Article	IF	Citations
271	Event Rates in Trials of Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2010, 303, 732.	3.8	0
272	Lower Treatment Blood Pressure Is Associated With Greatest Reduction in Hematoma Growth After Acute Intracerebral Hemorrhage. Hypertension, 2010, 56, 852-858.	1.3	75
273	Impact of Blood Pressure Lowering on Cardiovascular Outcomes in Normal Weight, Overweight, and Obese Individuals. Hypertension, 2010, 55, 1193-1198.	1.3	32
274	Event Rates, Hospital Utilization, and Costs Associated with Major Complications of Diabetes: A Multicountry Comparative Analysis. PLoS Medicine, 2010, 7, e1000236.	3.9	122
275	Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. European Heart Journal, 2010, 31, 1854-1864.	1.0	70
276	Effects of Perindopril-Based Lowering of Blood Pressure on Intracerebral Hemorrhage Related to Amyloid Angiopathy. Stroke, 2010, 41, 394-396.	1.0	188
277	Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. European Heart Journal, 2010, 31, 2888-2896.	1.0	85
278	Severe Hypoglycemia and Risks of Vascular Events and Death. New England Journal of Medicine, 2010, 363, 1410-1418.	13.9	1,279
279	Aspirin Is Beneficial in Hypertensive Patients With Chronic Kidney Disease. Journal of the American College of Cardiology, 2010, 56, 956-965.	1.2	171
280	Erectile Dysfunction and Later Cardiovascular Disease in Men With Type 2 Diabetes. Journal of the American College of Cardiology, 2010, 56, 1908-1913.	1.2	94
281	Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet, The, 2010, 375, 1875-1884.	6.3	788
282	Effects of Early Intensive Blood Pressure-Lowering Treatment on the Growth of Hematoma and Perihematomal Edema in Acute Intracerebral Hemorrhage. Stroke, 2010, 41, 307-312.	1.0	224
283	Variables tensionnelles etÂrisque cardiovasculaire chezÂlesÂdiabÃ©tiques deÂtype 2Âdans l'Ã©tude ADVANCE*. Sang Thrombose Vaisseaux, 2010, 22, 264-270.	0.1	0
284	Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes. Journal of the American Society of Nephrology: JASN, 2009, 20, 883-892.	3.0	245
285	Blood Pressure Variables and Cardiovascular Risk. Hypertension, 2009, 54, 399-404.	1.3	72
286	Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. European Heart Journal, 2009, 30, 1128-1135.	1.0	192
287	The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. European Heart Journal, 2009, 30, 1385-1394.	1.0	54
288	Effects of the End Point Adjudication Process on the Results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke, 2009, 40, 2111-2115.	1.0	26

#	Article	IF	Citations
289	Severe Cerebral White Matter Hyperintensities Predict Severe Cognitive Decline in Patients With Cerebrovascular Disease History. Stroke, 2009, 40, 2219-2221.	1.0	110
290	Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes. Diabetes Care, 2009, 32, 2068-2074.	4.3	230
291	Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes. Journal of the American Society of Nephrology: JASN, 2009, 20, 1813-1821.	3.0	787
292	ADVANCE: Blood Pressure Lowering in Diabetes. Journal of Clinical Hypertension, 2009, 11, 108-108.	1.0	0
293	Proteinuria and Stroke: A Meta-analysis of Cohort Studies. American Journal of Kidney Diseases, 2009, 53, 417-425.	2.1	128
294	An economic evaluation of a perindopril-based blood pressure lowering regimen for patients who have suffered a cerebrovascular event. European Journal of Health Economics, 2009, 10, 111-119.	1.4	6
295	Routine blood pressure lowering and intensive glucose control in patients with Type 2 diabetes: the ADVANCE trial. Expert Review of Endocrinology and Metabolism, 2009, 4, 111-118.	1.2	1
296	Response to Letter by Kerr and Nasco. Stroke, 2009, 40, .	1.0	0
297	Management of hypertension: evidence from the Blood Pressure Lowering Treatment Trialists' Collaboration and from major clinical trials. , 2009, 119, 373-80.		5
298	INTRODUCTION. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 361-361.	0.9	0
299	ADVANCES IN REDUCING THE BURDEN OF VASCULAR DISEASE IN TYPE 2 DIABETES. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 434-437.	0.9	6
300	Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurology, The, 2008, 7, 391-399.	4.9	732
301	Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2008, 358, 2560-2572.	13.9	6,447
302	The ADVANCE trial â€“ Authors' reply. Lancet, The, 2008, 371, 26.	6.3	1
303	Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. European Heart Journal, 2008, 29, 2669-2680.	1.0	225
304	Associations of Proinflammatory Cytokines With the Risk of Recurrent Stroke. Stroke, 2008, 39, 2226-2230.	1.0	142
305	Prevalence, Awareness, Treatment, and Control of Hypertension in China. Circulation, 2008, 118, 2679-2686.	1.6	467
306	UKPDS and the Legacy Effect. New England Journal of Medicine, 2008, 359, 1618-1620.	13.9	221

#	Article	IF	Citations
307	Antalya statement of the International Society of Hypertension on the prevention of blood pressure-related diseases. Journal of Hypertension, 2008, 26, 2255-2258.	0.3	0
308	Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence. Journal of Hypertension, 2008, 26, S21-S27.	0.3	5
309	The Relationship between Proteinuria and Coronary Risk: A Systematic Review and Meta-Analysis. PLoS Medicine, 2008, 5, e207.	3.9	189
310	Introduction: advances in the prevention of cardiovascular disease in patients with diabetes. Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension, 2008, 26, S1-2.	0.1	0
311	Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence. Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension, 2008, 26, S21-7.	0.1	4
312	Low-density lipoprotein particles and risk of intracerebral haemorrhage in subjects with cerebrovascular disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2007, 14, 413-418.	3.1	6
313	Chronic Kidney Disease, Cardiovascular Events, and the Effects of Perindopril-Based Blood Pressure Lowering. Journal of the American Society of Nephrology: JASN, 2007, 18, 2766-2772.	3.0	97
314	Introduction. Journal of Hypertension, 2007, 25, S1-S2.	0.3	0
315	New insights from ADVANCE. Journal of Hypertension, 2007, 25, S23-S30.	0.3	5
316	Perindopril-based blood pressure-lowering therapy reduces amino-terminal-pro-B-type natriuretic peptide in individuals with cerebrovascular disease. Journal of Hypertension, 2007, 25, 699-705.	0.3	8
317	Cerebrovascular Disease in Hypertension. , 2007, , 392-405.		0
318	Soluble Vascular Cell Adhesion Molecule 1 and N-terminal Proâ€“B-Type Natriuretic Peptide in Predicting Ischemic Stroke in Patients With Cerebrovascular Disease. Archives of Neurology, 2006, 63, 60.	4.9	41
319	ADVANCE: breaking new ground in type 2 diabetes. Journal of Hypertension, 2006, 24, S22-S28.	0.3	18
320	Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension, 2006, 24, 1201-1208.	0.3	262
321	Diuretics: A modern day treatment option? (Review Article). Nephrology, 2006, 11, 419-427.	0.7	14
322	Secondary prevention of stroke by blood pressure-lowering treatment. Current Hypertension Reports, 2006, 8, 317-323.	1.5	3
323	Blood pressure and stroke: a continuing debate. Journal of Hypertension, 2006, 24, 1249-1251.	0.3	2
324	Prior Events Predict Cerebrovascular and Coronary Outcomes in the PROGRESS Trial. Stroke, 2006, 37, 1497-1502.	1.0	59

#	Article	IF	Citations
325	ADVANCE: Lessons from the runâ€in phase of a large study in type 2 diabetes. Blood Pressure, 2006, 15, 340-346.	0.7	7
326	Blood pressure in acute stroke: in search of evidence. Journal of Hypertension, 2005, 23, 277-278.	0.3	13
327	Effects of Blood Pressure Lowering on Cerebral White Matter Hyperintensities in Patients With Stroke. Circulation, 2005, 112, 1644-1650.	1.6	422
328	Prediction of Myocardial Infarction by N-Terminal-Pro-B-Type Natriuretic Peptide, C-Reactive Protein, and Renin in Subjects With Cerebrovascular Disease. Circulation, 2005, 112, 110-116.	1.6	71
329	Effects of Different Blood Pressureâ€“Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus. Archives of Internal Medicine, 2005, 165, 1410.	4.3	710
330	Prediction of Heart Failure by Amino Terminal-proâ€“B-Type Natriuretic Peptide and C-Reactive Protein in Subjects With Cerebrovascular Disease. Hypertension, 2005, 45, 69-74.	1.3	39
331	Perindopril-Based Blood Pressureâ€“Lowering Reduces Major Vascular Events in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack. Stroke, 2005, 36, 2164-2169.	1.0	100
332	Associations of Inflammatory and Hemostatic Variables With the Risk of Recurrent Stroke. Stroke, 2005, 36, 2143-2147.	1.0	123
333	Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease. European Heart Journal, 2005, 26, 1910-1915.	1.0	47
334	Effects of Perindopril-Based Blood Pressure Lowering and of Patient Characteristics on the Progression of Silent Brain Infarct: the Perindopril Protection against Recurrent Stroke Study (PROGRESS) CT Substudy in Japan. Hypertension Research, 2004, 27, 147-156.	1.5	37
335	Reductions in the risks of recurrent stroke in patients with and without diabetes: The PROGRESS Trial. Blood Pressure, 2004, 13, 7-13.	0.7	72
336	The PROGRESS trial three years later: time for more action, less distraction. BMJ: British Medical Journal, 2004, 329, 970-971.	2.4	10
337	Comparison of Various Blood Pressure Lowering Treatments on the Primary Prevention of Cardiovascular Outcomes in Recent Randomised Clinical Trials. Clinical and Experimental Hypertension, 2004, 26, 709-719.	0.5	8
338	World Health Organisationâ€“International Society of Hypertension (WHO/ISH) Hypertension Guidelines. Clinical and Experimental Hypertension, 2004, 26, 747-752.	0.5	134
339	Effects of an Angiotensin-converting Enzyme Inhibitorâ€“based Regimen on Pneumonia Risk. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 1041-1045.	2.5	133
340	New strategies for hypertension control. American Journal of Cardiovascular Drugs, 2004, 4, 37-42.	1.0	0
341	Perindopril-based blood pressure lowering in individuals with cerebrovascular disease. Journal of Hypertension, 2004, 22, 653-659.	0.3	42
342	The management of blood pressure in acute stroke. Lancet Neurology, The, 2003, 2, 593.	4.9	7

#	Article	IF	Citations
343	Trials on blood pressureâ€“lowering and secondary stroke prevention. American Journal of Cardiology, 2003, 91, 3-8.	0.7	14
344	Diabetes and Vascular Disease: A New International Trial. Asian Cardiovascular and Thoracic Annals, 2003, 11, 180-184.	0.2	0
345	The ACE Gene I/D Polymorphism Is Not Associated With the Blood Pressure and Cardiovascular Benefits of ACE Inhibition. Hypertension, 2003, 42, 297-303.	1.3	129
346	Effects of Blood Pressure Lowering With Perindopril and Indapamide Therapy on Dementia and Cognitive Decline in Patients With Cerebrovascular Disease. Archives of Internal Medicine, 2003, 163, 1069.	4.3	780
347	International Society of Hypertension (ISH). Journal of Hypertension, 2003, 21, 649-650.	0.3	32
348	All hats off to ALLHAT. Journal of Hypertension, 2003, 21, 225-228.	0.3	12
349	Lowering blood pressure in 2003. Medical Journal of Australia, 2003, 179, 306-312.	0.8	5
350	International Society of Hypertension (ISH): statement on blood pressure lowering and stroke prevention. Journal of Hypertension, 2003, 21, 651-63.	0.3	37
351	Etude ADVANCE : objectifs, protocole et ??tat actuel. Drugs, 2003, 63, 39-44.	4.9	5
352	Enhancing risk stratification in hypertensive subjects: how far should we go in routine screening for target organ damage?. Journal of Hypertension, 2002, 20, 1255-1257.	0.3	13
353	The ABCD of anti-hypertensive therapy?. Journal of Hypertension, 2002, 20, 615-616.	0.3	3
354	The lowering of blood pressure after stroke. Lancet, The, 2001, 358, 1994-1995.	6.3	23
355	Challenges for the Prevention of Primary and Secondary Stroke. The importance of lowering blood pressure and total cardiovascular risk. Blood Pressure, 2001, 10, 344-351.	0.7	28
356	Blood Pressure Lowering In Diabetes: A Brief Review Of The Current Evidence And Description Of A New Trial. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 1108-1111.	0.9	6
357	Progress In Reducing The Burden Of Stroke*. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 1091-1095.	0.9	8
358	Differential expression of catecholamine biosynthetic enzymes in the rat ventrolateral medulla. Journal of Comparative Neurology, 2001, 432, 20-34.	0.9	83
359	Delta pioid receptor immunoreactive boutons appose bulbospinal CI neurons in the rat. NeuroReport, 2000, 11, 887-891.	0.6	15
360	Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients. Journal of Hypertension, 2000, 18, 327-334.	0.3	67

#	Article	IF	Citations
361	Calbindin-immunoreactive neurons in the reticular formation of the rat brainstem: Catecholamine content and spinal projections. Journal of Comparative Neurology, 2000, 424, 547-562.	0.9	35
362	Spinal GABA_A receptors do not mediate the sympathetic baroreceptor reflex in the rat. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2000, 279, R320-R331.	0.9	11
363	Connecting the dots: ongoing ace inhibition trials and what they can tell us Tuesday, may 16, broadway ballroom north, 5:30 pm to 7:30 pm. ace inhibitors: more than just bp reduction. American Journal of Hypertension, 2000, 13, S325.	1.0	0
364	Activation of spinal opioid receptors contributes to hypotension after hemorrhage in conscious rats. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 276, H1552-H1558.	1.5	17
365	The 1999 WHOâ€“ISH Guidelines for the Management of Hypertension. Medical Journal of Australia, 1999, 171, 458-459.	0.8	59
366	Identification of Posterior Cricoarytenoid Motoneurons in the Rat. Annals of Otology, Rhinology and Laryngology, 1999, 108, 1033-1041.	0.6	14
367	Intracellular Recording from Posterior Cricoarytenoid Motoneurons in the Rat. Annals of Otology, Rhinology and Laryngology, 1999, 108, 1120-1125.	0.6	11
368	Implementation of Guidelines for Management of Hypertension. Clinical and Experimental Hypertension, 1999, 21, 647-657.	0.5	18
369	Neurokinin-1 receptors and spinal cord control of blood pressure in spontaneously hypertensive rats. Brain Research, 1999, 815, 116-120.	1.1	12
370	Substance P-immunoreactive boutons closely appose inspiratory protruder hypoglossal motoneurons in the cat. Brain Research, 1999, 834, 155-159.	1.1	15
371	Efficacy and Safety of an Oral Fixed Low-Dose Perindopril 2 mg/Indapamide 0.625 mg Combination: A Randomized, Double-Blind, Placebo-Controlled Study in Elderly Patients with Mild to Moderate Hypertension. Clinical and Experimental Hypertension, 1999, 21, 1097-1110.	0.5	26
372	The Importance of Drug Combinations for Effective Control of Hypertension. Clinical and Experimental Hypertension, 1999, 21, 875-884.	0.5	17
373	The pre-BÃ¶tzinger complex and phase-spanning neurons in the adult rat. Brain Research, 1998, 809, 204-213.	1.1	85
374	Volhard Lecture Brain, blood pressure and stroke. Journal of Hypertension, 1998, 16, 1849-1858.	0.3	23
375	Blood Pressure Lowering for the Prevention of Cognitive Decline in Patients with Cerebrovascular Disease. Clinical and Experimental Hypertension, 1997, 19, 843-855.	0.5	19
376	Respiratory Activity of the Rat Posterior Cricoarytenoid Muscle. Annals of Otology, Rhinology and Laryngology, 1997, 106, 897-901.	0.6	13
377	Lacidipine, hydrochlorothiazide and their combination in systolic hypertension in the elderly. Journal of Hypertension, 1997, 15, 1503-1510.	0.3	8
378	c-fos identifies GABA-synthesizing barosensitive neurons in caudal ventrolateral medulla. NeuroReport, 1997, 8, 3015-3021.	0.6	48

#	Article	IF	Citations
379	Reliable and unbiased assessment of the effects of calcium antagonists. Journal of Hypertension, 1997, 15, 1201-1204.	0.3	14
380	Phosphate-activated glutaminase immunoreactivity in brainstem respiratory neurons. Journal of the Autonomic Nervous System, 1997, 63, 85-90.	1.9	13
381	Role of spinal GABA receptors in depressor responses to chemical stimulation of the A5 area in normal and hypertensive rats. Journal of the Autonomic Nervous System, 1997, 66, 53-61.	1.9	9
382	Central control mechanisms in hypertension. Australian and New Zealand Journal of Medicine, 1997, 27, 474-478.	0.5	6
383	Bï¿½tzinger neurons project towards bulbospinal neurons in the rostral ventrolateral medulla of the rat. , 1997, 388, 23-31.		51
384	Blood Pressure Lowering for the Secondary Prevention of Myocardial Infarction and Stroke. Hypertension, 1997, 29, 537-538.	1.3	30
385	Respiratory Inputs to Central Cardiovascular Neurons. Annals of the New York Academy of Sciences, 1996, 783, 64-70.	1.8	14
386	Altered responsiveness of medullary depressor neurones to L-glutamate and D-serine in SHR rats. NeuroReport, 1996, 7, 1409-1412.	0.6	7
387	Thyrotropin-releasing hormone immunoreactive boutons form close appositions with medullary expiratory neurons in the rat. Brain Research, 1996, 715, 136-144.	1.1	20
388	AMPA/kainate receptors mediate sympathetic chemoreceptor reflex in the rostral ventrolateral medulla. Brain Research, 1996, 726, 64-68.	1.1	23
389	The treatment of hypertension. British Journal of Clinical Pharmacology, 1996, 42, 29-35.	1.1	6
390	TACHYCARDIA AFTER GLUTAMATE INJECTION IN RAT SPINAL CORD IS NOT BLOCKED BY KYNURENATE OR MIMICKED BY METABOTROPIC AGONISTS. Clinical and Experimental Pharmacology and Physiology, 1996, 23, 813-818.	0.9	6
391	BLOOD PRESSURE LOWERING IN PATIENTS WITH CEREBROVASCULAR DISEASE: RESULTS OF THE PROGRESS (PERINDOPRIL PROTECTION AGAINST RECURRENT STROKE STUDY) PILOT PHASE. Clinical and Experimental Pharmacology and Physiology, 1996, 23, 444-446.	0.9	11
392	Altered c -fos in Rostral Medulla and Spinal Cord of Spontaneously Hypertensive Rats. Hypertension, 1996, 27, 433-441.	1.3	66
393	Serotonin inputs to rabbit sympathetic preganglionic neurons projecting to the superior cervical ganglion or adrenal medulla. Journal of Comparative Neurology, 1995, 353, 427-438.	0.9	34
394	Synapses on axons of sympathetic preganglionic neurons in rat and rabbit thoracic spinal cord. Journal of Comparative Neurology, 1995, 354, 193-208.	0.9	26
395	Effect of Indomethacin on Blood Pressure Control during Treatment with Nitrendipine. Blood Pressure, 1995, 4, 307-312.	0.7	13
396	Antisense to Thyrotropin Releasing Hormone Receptor Reduces Arterial Blood Pressure in Spontaneously Hypertensive Rats. Circulation Research, 1995, 77, 679-683.	2.0	22

#	Article	IF	Citations
397	The National Consensus Conferenceâ€"Not Always What It Seems. Blood Pressure, 1994, 3, 4-6.	0.7	9
398	Mono- and Combination Therapy with Felodipine or Enalapril in Elderly Patients with Systolic Hypertension. Blood Pressure, 1994, 3, 90-96.	0.7	17
399	Close appositions between Tyrosine hydroxylase immunoreactive boutons and respiratory neurons in the rat ventrolateral medulla. Journal of Comparative Neurology, 1994, 340, 1-10.	0.9	75
400	Intracellular recording from sympathetic preganglionic neurons in cat lumbar spinal cord. Brain Research, 1994, 656, 319-328.	1.1	34
401	CENTRAL NEURONS AND NEUROTRANSMITTERS IN THE CONTROL OF BLOOD PRESSURE. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 819-829.	0.9	27
402	KYNURENIC ACID, AN ENDOGENOUS GLUTAMATE ANTAGONIST, IN SHR AND WKY RATS: POSSIBLE ROLE IN CENTRAL BLOOD PRESSURE REGULATION. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 891-896.	0.9	41
403	Mild hypertension: A summary of the 1993 World Health Organization/International Society of Hypertension (WHO/ISH) guidelines for the management of mild hypertension Memorandum from a WHO/ISH meetingâ€. Journal of Internal Medicine, 1994, 235, 21-29.	2.7	8
404	Projections from inspiratory neurons of the ventral respiratory group to the subretroficial nucleus of the cat. Brain Research, 1994, 633, 63-71.	1.1	31
405	Felodipine, Metoprolol and Their Combination Compared with Placebo in Isolated Systolic Hypertension in the Elderly. Blood Pressure, 1994, 3, 82-89.	0.7	19
406	The HOT Study: Design and Cost of Major Blood Pressure Trials. Blood Pressure, 1994, 3, 276-278.	0.7	3
407	The Place of Combination Therapy in the Treatment of Hypertension in 1993. Clinical and Experimental Hypertension, 1993, 15, 1299-1313.	0.5	39
408	Are the Ventrally Projecting Dendrites of Respiratory Neurons a Neuroanatomical Basis for the Chemosensitivity of the Ventral Medulla Oblongata?. Sleep, 1993, , .	0.6	4
409	Amino acid neurotransmitters in the central control of blood pressure and in experimental hypertension. Journal of Hypertension, 1992, 10, S27???38.	0.3	27
410	Ventral medulla stimulation increases blood pressure and spinal cord amino acid release. NeuroReport, 1992, 3, 55-58.	0.6	37
411	KAINIC ACID INJECTION IN NTS EVOKES HYPERTENSION AND C-FOS EXPRESSION IN SPINAL CORD. NeuroReport, 1992, 3, 437-440.	0.6	12
412	Sympathetic preganglionic neurons in rabbit spinal cord that project to the stellate or the superior cervical ganglion. Brain Research, 1992, 577, 181-188.	1.1	33
413	Sympathetic preganglionic neurons projecting to the adrenal medulla and aorticorenal ganglion in the rabbit. Brain Research, 1992, 586, 125-129.	1.1	9
414	AXONAL PROJECTIONS FROM RESPIRATORY CENTRES TOWARDS THE ROSTRAL VENTROLATERAL MEDULLA IN THE RAT. Clinical and Experimental Pharmacology and Physiology, 1992, 19, 335-338.	0.9	14

#	Article	IF	Citations
415	Substance P immunoreactive boutons form synapses with feline sympathetic preganglionic neurons. Journal of Comparative Neurology, 1992, 320, 121-135.	0.9	67
416	Women in Medicine. Medical Journal of Australia, 1992, 157, 726-727.	0.8	1
417	Glutamate in spinally projecting neurons of the rostral ventral medulla. Brain Research, 1991, 555, 326-331.	1.1	87
418	Opioid innervation of the caudal ventrolateral medulla is not critical for the expression of the aortic depressor nerve response in the rabbit. Journal of the Autonomic Nervous System, 1991, 32, 37-46.	1.9	5
419	Brainstem and bulbospinal neurotransmitter systems in the control of blood pressure. Journal of Hypertension, 1991, 9, 675-694.	0.3	236
420	THERE ARE FEW CATECHOLAMINE- OR NEUROPEPTIDE Y-CONTAINING SYNAPSES IN THE INTERMEDIOLATERAL CELL COLUMN OF RAT THORACIC SPINAL CORD. Clinical and Experimental Pharmacology and Physiology, 1991, 18, 111-115.	0.9	14
421	Severe Amnesia After Hypoglycemia: Clinical, Psychometric, and Magnetic Resonance Imaging Correlations. Diabetes Care, 1991, 14, 922-925.	4.3	105
422	Afferent Inputs to Ventrolateral Medulla. , 1991, , 3-13.		0
423	Lack of effect of fish oil supplementation on blood pressure in treated hypertensives. Journal of Hypertension, 1990, 8, 339-343.	0.3	35
424	Diltiazem and atenolol in essential hypertension: additivity of effects on blood pressure and cardiac conduction with combination therapy. Journal of Hypertension, 1990, 8, 1015-1019.	0.3	12
425	Differences in the Central Hypotensive Actions of Î±-Methyldopa and Clonidine in the Spontaneously Hypertensive Rat. Journal of Cardiovascular Pharmacology, 1990, 15, 118-123.	0.8	17
426	A LACK OF POTENCY FOR THE ?-OPIOID ANTAGONIST NALTRINDOLE AFTER MICROINJECTION INTO THE ROSTRAL VENTROLATERAL MEDULLA OF RABBITS. Clinical and Experimental Pharmacology and Physiology, 1990, 17, 527-530.	0.9	4
427	Central serotonergic mechanisms in cardiovascular regulation. Cardiovascular Drugs and Therapy, 1990, 4, 27-32.	1.3	31
428	Quantitative analysis of spinally projecting adrenaline-synthesising neurons of C1, C2 and C3 groups in rat medulla oblongata. Journal of the Autonomic Nervous System, 1990, 30, 209-220.	1.9	68
429	Effects of neuropeptide Y on the renal, mesenteric and hindlimb vascular beds of the conscious rabbit. Journal of the Autonomic Nervous System, 1989, 27, 139-146.	1.9	19
430	Evidence for an excitatory amino acid pathway in the brainstem and for its involvement in cardiovascular control. Brain Research, 1989, 496, 401-407.	1.1	116
431	Correlation between fall in blood pressure and in vivo amine release after Î±-methylDOPA. European Journal of Pharmacology, 1989, 164, 531-538.	1.7	2
432	Optimal size of cuff bladder for indirect measurement of arterial pressure in adults. Journal of Hypertension, 1989, 7, 607-613.	0.3	49

#	Article	IF	Citations
433	Release of substance P in the nucleus tractus solitarius measured by in vivo microdialysis: response to stimulation of the aortic depressor nerves in rabbit. Neuroscience Letters, 1988, 94, 131-137.	1.0	59
434	Effects of Intrathecal Administration of Methysergide, Phentolamine, and Pindolol on Pressor Responses to Electrical Stimulation of the Rostral Ventrolateral Medulla. Journal of Cardiovascular Pharmacology, 1988, 11, 456-460.	0.8	21
435	Plasma Neuropeptide Y Concentration Is Increased After Hemorrhage in Conscious Rats. Journal of Cardiovascular Pharmacology, 1987, 9, 541-545.	0.8	77
436	The use of microinjected colloidal gold and immunocytochemistry to localise pressor sites in the rostral medulla oblongata of the rat. Neuroscience Letters, 1987, 77, 125-130.	1.0	16
437	Do pressor neurons in the ventrolateral medulla release amines and neuropeptides?. Canadian Journal of Physiology and Pharmacology, 1987, 65, 1598-1604.	0.7	12
438	COMPLEMENTARY CHANGES IN PLASMA ATRIAL NATRIURETIC PEPTIDE AND ANTIDIURETIC HORMONE CONCENTRATIONS IN RESPONSE TO VOLUME EXPANSION AND HAEMORRHAGE: STUDIES IN CONSCIOUS NORMOTENSIVE AND SPONTANEOUSLY HYPERTENSIVE RATS. Clinical and Experimental Pharmacology and Physiology, 1987, 14, 283-289.	0.9	11
439	Does substance P coexist with adrenaline in neurones of the rostral ventrolateral medulla in the rat?. Neuroscience Letters, 1986, 71, 293-298.	1.0	47
440	Relative Importance of Sympathetic Nerves and of Circulating Adrenaline and Vasopressin in Mediating Hypertension After Lesions of the Caudal Ventrolateral Medulla in the Rat. Journal of Hypertension, 1986, 4, 273-281.	0.3	16
441	Effects of Sinoaortic Baroreceptor Denervation on Blood Pressure and PNMT Activity in Medulla Oblongata and Spinal Cord of Normotensive and Genetically Hypertensive Rats. Journal of Hypertension, 1985, 3, 81-87.	0.3	21
442	Effects of Vasopressin on Heart Rate in Conscious Rabbits. Journal of Cardiovascular Pharmacology, 1985, 7, 6-11.	0.8	31
443	Renal sympathetic nerve responses to stimulation, inhibition and destruction of the ventrolateral medulla in the rabbit. Neuroscience Letters, 1985, 60, 51-55.	1.0	44
444	Cardiovascular effects of intracisternal 6-hydroxydopamine and of subsequent lesions of the ventrolateral medulla coinciding with the A1 group of noradrenaline cells in the rabbit. Journal of the Autonomic Nervous System, 1985, 12, 117-130.	1.9	4
445	IMPORTANCE OF CENTRAL SEROTONIN NEURONS IN THE HYPOTENSIVE ACTION OF METHYLDOPA IN THE RAT. Clinical and Experimental Pharmacology and Physiology, 1984, 11, 37-44.	0.9	10
446	EFFERENT MECHANISMS RESPONSIBLE FOR THE BRADYCARDIA PRODUCED BY LESIONS COINCIDING WITH THE A1 GROUP OF CENTRAL CATECHOLAMINE NEURONS IN THE CONSCIOUS RABBIT. Clinical and Experimental Pharmacology and Physiology, 1984, 11, 143-154.	0.9	1
447	EFFECTS OF TIMOLOL AND HYDROCHLOROTHIAZIDE ON BLOOD-PRESSURE AND PLASMA RENIN ACTIVITY Double-blind Factorial Trial. Lancet, The, 1976, 308, 328-331.	6.3	45
448	Assessment of cardiac autonomic excitability in renal hypertensive rabbits using clonidine-induced resetting of the baroreceptor-heart rate reflex. European Journal of Pharmacology, 1975, 33, 353-362.	1.7	17
449	Effects of clonidine on the baroreceptor-heart rate reflex and on single aortic baroreceptor fibre discharge. European Journal of Pharmacology, 1974, 28, 189-198.	1.7	93
450	Participation of Central Serotonergic Neurons in the Control of the Circulation of the Unanesthetized Rabbit. Circulation Research, 1974, 35, 504-513.	2.0	62

#	Article	IF	Citations
451	Role of the Autonomic Nervous System in the Renal Vasoconstriction Response to Hemorrhage in the Rabbit. Circulation Research, 1967, 20, 676-685.	2.0	31